Wolfe Research initiated coverage of Kestra Medical (KMTS) with an Outperform rating and $29 price target Kestra, which launched its ASSURE wearable cardioverter defibrillator in the U.S. in 2022, is second to market and seeking to take material share from sole incumbent ZOLL Medical (ZOLL) and growing the category, the analyst tells investors. Early signs suggest Kestra’s positive evolution of the WCD concept is driving share capture, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMTS:
- Kestra Medical initiated with an Overweight at Wells Fargo
- Kestra Medical initiated with a Buy at Stifel
- Kestra Medical initiated with an Overweight at Piper Sandler
- Kestra Medical Technologies: Positioned for Growth with Next-Gen Wearable Cardioverter Defibrillator
- Buy Rating for Kestra Medical Technologies Ltd. Driven by Strong Growth Prospects and Strategic Market Positioning